ACRX - AcelRx Pharmaceuticals, Inc.
3.16 -0.04 (-1.25%)
After hours: 7:13PM EST
| Previous Close | 3.2600 |
| Open | 3.2400 |
| Bid | 3.16 x 1000 |
| Ask | 3.24 x 1000 |
| Day's Range | 2.9300 - 3.2800 |
| 52 Week Range | 1.6500 - 5.0500 |
| Volume | 3,864,199 |
| Avg. Volume | 1,937,558 |
| Market Cap | 244.459M |
| Beta (3Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.21 |
- PR Newswire•15 hours ago
AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial ...
- ACCESSWIRE•4 days ago
Biotech Leaders to Watch This Week
HENDERSON, NV / ACCESSWIRE / February 19, 2019 / Biotechnology is coming back strong in 2019 as the iShares Nasdaq Biotechnology Index's 16% surge higher during the first month and a half of this new year ...
- ACCESSWIRE•4 days ago
4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.
- Zacks•12 days ago
Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
Is (ACRX) Outperforming Other Medical Stocks This Year?
- PR Newswire•23 days ago
AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services — Discovering Underlying Factors of Influence
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis - Initial dosing of 30 mcg sufentanil sublingual tablet calculated as dose-equivalent to ...
- Motley Fool•2 months ago
2 Biotech Penny Stocks to Buy Right Now
AcelRx and Novavax are two penny biotech stocks worth checking out in this latest market downturn.
- Insider Monkey•2 months ago
Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
- Zacks•2 months ago
Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
- PR Newswire•2 months ago
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
- Motley Fool•3 months ago
3 Stocks to Hold for the Next 20 Years
When you invest in a business, you should expect to stay with it for the long haul.
- PR Newswire•3 months ago
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), ...
- ACCESSWIRE•3 months ago
New Healthcare Trends Could Push Sector Stocks Higher
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 AcelRx Pharmaceuticals Inc Earnings Call
- PR Newswire•3 months ago
AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
REDWOOD CITY, Calif. , Nov. 14, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Motley Fool•3 months ago
Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
- PR Newswire•3 months ago
AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about November 14, 2018, subject to the satisfaction of customary closing conditions.
- PR Newswire•3 months ago
AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Credit Suisse Securities (USA) LLC, Jefferies LLC, Cantor Fitzgerald & Co. and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.
- PR Newswire•4 months ago
AcelRx Pharmaceuticals to Present at Credit Suisse 27th Annual Healthcare Conference
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
American City Business Journals•4 months agoHealth Care Digest: Health's push onto the ballot, an exec's cancer story and more
More health care issues are being decided at the ballot box, and Tuesday's election isn't the end of the trend.
- Motley Fool•4 months ago
Why AcelRx Pharmaceuticals Stock Is Slipping Today
Nothing to worry about after the biotech received a much-needed FDA approval last week.
- ACCESSWIRE•4 months ago
Monday's Top Healthcare Stocks To Watch Ahead Of Elections
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
